Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin #3 [December 2018]

Product Code:
596201002
Publication Date:
December 2018
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the rheumatoid arthritis (RA) market. Topics covered include: Gilead Sciences and Galapagos announcing that the investigational JAK1 inhibitor filgotinib, achieved the primary endpoint of the Phase III FINCH 2 study involving adults with moderately-to-severely active RA who had an inadequate response or intolerance to prior biologic agents; GlaxoSmithKline announcing results from a Phase II dose-ranging study of GSK3196165, an investigational anti-granulocyte macrophage colony-stimulating factor monoclonal (anti GM-CSF) antibody; as well as Eli Lilly and Incyte announcing findings from an updated integrated safety analysis of Olumiant (baricitinib) based on an ongoing long-term extension (LTE) study of RA patients treated up to six years.

Business Questions:

• What are KOLs’ reactions to the filgotinib FINCH 2 results?
• What do experts consider critical in determining filgotinib’s success?
• How do KOLs view GSK 3196165’s mechanism of action?
• What concerns do KOLs have regarding GSK 3196165?
• According to KOLs, how important is the updated integrated safety analysis of Olumiant (baricitinib)?
• According to experts, how is Olumiant currently faring in the US and EU?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved